PATENT CLAIM ANALYSIS

Application Number: 16400198
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-08
Patent Classification: ["530", "388220"]

Abstract:
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the Lymphocyte Activation Gene-3 (LAG-3). The invention provides a LAG-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the LAG-3-binding agent to treat a disorder or disease that is responsive to LAG-3 inhibition, such as cancer or an infectious disease.

Claim (Index 50):
A Lymphocyte Activation Gene-3 (LAG-3) binding agent comprising:\n an immunoglobulin light chain variable (V L ) region comprising a light chain CDR1, a light chain CDR2, and a light chain CDR3 of SEQ ID NO:88; and an immunoglobulin heavy chain variable (V H ) region comprising a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of SEQ ID NO:182.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 100.0
- Lexical Diversity: 1.78
- Patent Class: 530.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15563924', '15567045', '12599430', '11323261', '11929729']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7437478145365967
- 35 USC 102 Novelty (BERT): 0.607160827768966
- Combined Prediction Score: 0.7300891158598336
- Mean Citation Score: 478.760874
- Max Citation Score: 593.3006
- Similarity Product: 481.0200219692707

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test